Galecto (GLTO)
(Delayed Data from NSDQ)
$0.52 USD
+0.03 (7.15%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $0.51 -0.01 (-1.92%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Galecto, Inc. [GLTO]
Reports for Purchase
Showing records 1 - 7 ( 7 total )
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Preliminary Data Suggest GB1211 Lung Cancer Potential; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Strategic Reprioritization and Restructuring Initiated; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
GALACTIC-1 Study Failure; Reiterate Buy; Lowering PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Key Milestones Approaching; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PACHAIYAPPAN B
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
GALACTIC-1 Study Dosing Concluded; Top-Line Data in August; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
Disrupting Fibrosis and Cancer Treatment; Initiating at Buy and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Galecto, Inc.
Industry: Medical - Biomedical and Genetics
|